兴齐眼药前三季度净利润5.99亿元 同比增长105.98%

Core Insights - Shenyang Xingqi Eye Pharmaceutical Co., Ltd. continues to experience rapid growth in revenue and profit, with a significant increase in both metrics for the third quarter of 2025 [1] Financial Performance - For the first three quarters of this year, the company achieved operating revenue of 1.904 billion yuan, a year-on-year increase of 32.27% [1] - The net profit attributable to shareholders reached 599 million yuan, reflecting a year-on-year growth of 105.98% [1] - In the third quarter alone, the company reported operating revenue of 741 million yuan, up 35.34% year-on-year, and a net profit of 264 million yuan, which is a 117.45% increase year-on-year [1] Product Development and Market Position - The company specializes in the ophthalmic drug sector, maintaining a leading position in research and development, with a comprehensive product line [1] - Xingqi Eye Pharmaceutical has developed a diverse range of ophthalmic products, including treatments for myopia, dry eye, infections, inflammation, and glaucoma, covering ten subcategories of ophthalmic drugs [1] - The growth in revenue is primarily attributed to increased sales of eye drop products [1] Innovation and R&D Focus - Since its inception, the company has prioritized the development of new products with independent intellectual property rights as a key goal for continuous improvement and innovation [2] - Recent product approvals include cyclosporine eye drops and atropine sulfate eye drops, contributing to rapid revenue and profit growth [2] - New products such as tafluprost eye drops have received drug registration certificates, and several others are in various stages of clinical trials [2]